Users Stopping Anti-Obesity Jabs Gain Back Weight at a Quadrupled Rate Compared to Those on Conventional Diets

New research reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who stop traditional lifestyle plans.

Research printed in a prominent medical journal shows that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month once they quit.

"Users purchasing these drugs should be informed of the potential of quick weight regain when the therapy ends," cautioned expert Dr. Susan Jebb.

That rate of recovery means a reversion to starting mass in about a year and a half.

Weighing Treatments

The research, which looked at 37 of studies involving thousands of patients, contrasted the results of the injectable medications with conventional dieting.

Researchers note that people who shed pounds through dieting typically have a more gradual weight regain—around 0.1 kg a month—after stopping.

Explaining the Quick Regain

Experts suggest the way of the jabs accounts for the accelerated regain.

The injections imitate a natural hormone called GLP-1, which controls hunger.

"Artificially providing the hormone concentrations far above than normal could lead to the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.

"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating a significant risk."

A Lifelong Condition?

Health authorities suggest the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.

A number of clinicians argue that, given the significant potential of relapse, the treatment might need to be life-long.

This perspective is supported by drug manufacturers, who state that the findings "underscore the persistent character of obesity," akin to managing diseases like diabetes.

Patient Experiences

Users who have stopped the medication describe a sudden resurgence of cravings.

"It felt as if a switch that goes on and you're instantly extremely hungry," said one woman.

The struggle is worsened if users have not established sustainable dietary or behavioural modifications during therapy.

Significant Interest

Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.

• Use is higher among females than males.
• The middle-aged age group shows the greatest level of interest.
• A large proportion access the drugs through private prescriptions rather than the NHS.

In conclusion, researchers stress that while these medications are powerful agents for weight loss, they are not a standalone fix and lasting health benefits likely depends on combined lifestyle support.